$UPC
Universe Pharmaceuticals Inc Stock $upc

$upc Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 20-F Financial Statement

#000121390023010349 Filed on February 10, 2023

Income Statement

Concept	2022 Q3	2022	2021 Q3
Revenue	$15.94M	$40.14M	$47.98M
YoY Change	-66.78%	-16.34%	56.27%
Cost Of Revenue	$7.806M	$18.25M	$22.66M
YoY Change	-65.55%	-19.44%	36.4%
Gross Profit	$8.135M	$21.89M	$25.33M
YoY Change	-67.88%	-13.56%	79.7%
Gross Profit Margin	51.03%	54.53%	52.78%
Selling, General & Admin	$10.78M	$21.69M	$6.098M
YoY Change	76.7%	255.63%	98.61%
% of Gross Profit	132.45%	99.06%	24.08%
Research & Development	$7.500M	$7.644M	$5.447M
YoY Change	37.69%	40.34%	860.29%
% of Gross Profit	92.19%	34.92%	21.51%
Depreciation & Amortization	$241.8K	$533.9K	$203.4K
YoY Change	18.89%	19.48%	1.66%
% of Gross Profit	2.97%	2.44%	0.8%
Operating Expenses	$18.27M	$29.33M	$11.74M
YoY Change	55.72%	149.92%	205.46%
Operating Profit	-$10.14M	-$7.439M	$13.59M
YoY Change	-174.61%	-154.74%	32.56%
Interest Expense	-$35.42K	$162.4K	-$70.77K
YoY Change	-49.95%	-329.48%	-30.58%
% of Operating Profit			-0.52%
Other Income/Expense, Net	-$1.119M	-$545.3K	$160.7K
YoY Change	-796.21%	-439.42%	-425.57%
Pretax Income	-$11.29M	-$7.984M	$13.68M
YoY Change	-182.57%	-158.37%	35.42%
Income Tax	-$825.8K	$752.4K	$2.359M
% Of Pretax Income			17.24%
Net Earnings	-$10.47M	-$8.737M	$11.32M
YoY Change	-192.48%	-177.18%	49.77%
Net Earnings / Revenue	-65.67%	-21.76%	23.59%
Basic Earnings Per Share		-$0.40
Diluted Earnings Per Share	-$0.48	-$0.40	$596.4K
COMMON SHARES
Basic Shares Outstanding	21.75M shares	21.75M shares
Diluted Shares Outstanding		21.75M shares

Balance Sheet

Concept	2022 Q3	2022	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.86M	$5.711M	$8.078M
YoY Change	133.48%	-29.3%	-19.69%
Cash & Equivalents	$5.711M		$8.078M
Short-Term Investments	$13.15M
Other Short-Term Assets	$5.255M	$18.40M	$24.37M
YoY Change	-78.43%	-24.47%	5391.62%
Inventory	$2.206M	$2.206M	$2.463M
Prepaid Expenses
Receivables	$15.18M	$15.18M	$15.57M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$41.51M	$41.51M	$50.48M
YoY Change	-17.78%	-17.78%	116.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.251M	$13.58M	$15.39M
YoY Change	-72.39%	-11.8%	247.64%
Goodwill
YoY Change
Intangibles	$157.5K		$178.5K
YoY Change	-11.78%
Long-Term Investments	$702.9K	$702.9K	$744.9K
YoY Change	-5.64%	-5.64%	1.35%
Other Assets	$3.597M	$3.597M	$3.347M
YoY Change	7.47%	7.47%	1694.15%
Total Long-Term Assets	$18.03M	$18.03M	$19.66M
YoY Change	-8.29%	-8.29%	255.94%
TOTAL ASSETS
Total Short-Term Assets	$41.51M	$41.51M	$50.48M
Total Long-Term Assets	$18.03M	$18.03M	$19.66M
Total Assets	$59.54M	$59.54M	$70.14M
YoY Change	-15.12%	-15.12%	143.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.075M	$3.075M	$5.311M
YoY Change	-42.09%	-42.09%	97.33%
Accrued Expenses	$2.539M	$2.539M	$444.3K
YoY Change	471.52%	471.52%	18.18%
Deferred Revenue
YoY Change
Short-Term Debt	$3.936M	$7.315M	$4.354M
YoY Change	-9.6%	68.01%	20.86%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.10M	$13.10M	$11.21M
YoY Change	16.83%	16.83%	40.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.10M	$13.10M	$11.21M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$13.10M	$13.10M	$11.21M
YoY Change	16.83%	16.83%	40.11%
SHAREHOLDERS EQUITY
Retained Earnings	$16.32M		$25.06M
YoY Change	-34.86%
Common Stock	$67.97K		$67.97K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$46.44M	$46.44M	$58.93M
YoY Change
Total Liabilities & Shareholders Equity	$59.54M	$59.54M	$70.14M
YoY Change	-15.12%	-15.12%	143.52%

Cashflow Statement

Concept	2022 Q3	2022	2021 Q3
OPERATING ACTIVITIES
Net Income	-$10.47M	-$8.737M	$11.32M
YoY Change	-192.48%	-177.18%	49.77%
Depreciation, Depletion And Amortization	$241.8K	$533.9K	$203.4K
YoY Change	18.89%	19.48%	1.66%
Cash From Operating Activities	-$7.431M	-$1.312M	-$3.114M
YoY Change	138.62%	-36.17%	37.49%
INVESTING ACTIVITIES
Capital Expenditures	$38.07K	$93.70K	-$393.6K
YoY Change	-109.67%	-121.08%	21768.33%
Acquisitions
YoY Change
Other Investing Activities	-$3.815M	-$3.814M	-$26.62M
YoY Change	-85.67%	-85.67%
Cash From Investing Activities	-$3.853M	-$3.908M	-$27.01M
YoY Change	-85.73%	-85.56%	1500404.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.808M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.338M	$3.318M	2.445M
YoY Change	36.51%	-87.52%	2120.13%
NET CHANGE
Cash From Operating Activities	-7.431M	-$1.312M	-3.114M
Cash From Investing Activities	-3.853M	-$3.908M	-27.01M
Cash From Financing Activities	3.338M	$3.318M	2.445M
Net Change In Cash	-7.946M	-$2.366M	-27.68M
YoY Change	-71.29%	-6.61%	1183.46%
FREE CASH FLOW
Cash From Operating Activities	-$7.431M	-$1.312M	-$3.114M
Capital Expenditures	$38.07K	$93.70K	-$393.6K
Free Cash Flow	-$7.469M	-$1.406M	-$2.720M
YoY Change	174.55%	-12.74%	20.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering		usd
CY2022Q3	upc	Sunsequent Collection Allowance For Doubtful Accounts SunsequentCollectionAllowanceForDoubtfulAccounts		usd
CY2022	upc	Allowance For Doubtful Accounts Receivable Percentage AllowanceForDoubtfulAccountsReceivablePercentage		pure
CY2021	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions		usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations		usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2020Q3	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2022	upc	Add Purchase Wealth Management Financial Products AddPurchaseWealthManagementFinancialProducts		usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2020Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments		usd
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent		usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness		pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate		pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance		pure
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40231
CY2022	dei	Entity Registrant Name EntityRegistrantName	Universe Pharmaceuticals INC
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	265 Jingjiu Avenue,
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Jinggangshan Economic and Technological Development Zone
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Ji’an, Jiangxi
CY2022	dei	Entity Address Country EntityAddressCountry	CN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	343100
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares
CY2022	dei	Trading Symbol TradingSymbol	UPC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21750000	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Name AuditorName	YCM CPA, Inc.
CY2022	dei	Auditor Firm AuditorFirmId	6781
CY2022	dei	Auditor Location AuditorLocation	Irvine, California
CY2022Q3	us-gaap	Cash Cash	5711458	usd
CY2021Q3	us-gaap	Cash Cash	8077908	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	13148594	usd
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	13725204	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15183890	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15573742	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	2206488	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	2462542	usd
CY2021Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	236982	usd
CY2022Q3	us-gaap	Supplies Supplies	16701	usd
CY2021Q3	us-gaap	Supplies Supplies	2738313	usd
CY2021Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	7492320	usd
CY2022Q3	upc	Prepayment For Acquisition Current PrepaymentForAcquisitionCurrent	3514450	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1724099	usd
CY2021Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	174053	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	41505680	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	50481064	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4250638	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4681353	usd
CY2022Q3	upc	Prepayments Made To A Related Party For Purchase Of Property Non Current PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent	2249248	usd
CY2021Q3	upc	Prepayments Made To A Related Party For Purchase Of Property Non Current PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent	2476800	usd
CY2022Q3	upc	Prepayments For Construction In Progress PrepaymentsForConstructionInProgress	9326296	usd
CY2021Q3	upc	Prepayments For Construction In Progress PrepaymentsForConstructionInProgress	10712160	usd
CY2022Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	157451	usd
CY2021Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	178483	usd
CY2022Q3	upc	Investment In Equity Securities InvestmentInEquitySecurities	702890	usd
CY2021Q3	upc	Investment In Equity Securities InvestmentInEquitySecurities	744924	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1347672	usd
CY2021Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	869997	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	18034195	usd
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	19663717	usd
CY2022Q3	us-gaap	Assets Assets	59539875	usd
CY2021Q3	us-gaap	Assets Assets	70144781	usd
CY2022Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	3936184	usd
CY2021Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	4334400	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3075393	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5310526	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	167350	usd
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	1101460	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3379263	usd
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	19723	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2539362	usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	444319	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13097552	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11210428	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.003125
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.003125
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21750000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21750000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21750000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21750000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	67969	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	67969	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29279159	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29279159	usd
CY2022Q3	upc	Statutory Reserve StatutoryReserve	2439535	usd
CY2021Q3	upc	Statutory Reserve StatutoryReserve	2439535	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	16322365	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25058931	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1666705	usd
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2088759	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46442323	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	58934353	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59539875	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70144781	usd
CY2022	us-gaap	Revenues Revenues	40143151	usd
CY2021	us-gaap	Revenues Revenues	47982031	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-12492030	usd
CY2020	us-gaap	Profit Loss ProfitLoss	7558222	usd
CY2020	us-gaap	Revenues Revenues	30703960	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	18251815	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	22655854	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	16610140	usd
CY2022	us-gaap	Gross Profit GrossProfit	21891336	usd
CY2021	us-gaap	Gross Profit GrossProfit	25326177	usd
CY2020	us-gaap	Gross Profit GrossProfit	14093820	usd
CY2022	us-gaap	Selling Expense SellingExpense	19083135	usd
CY2021	us-gaap	Selling Expense SellingExpense	2973531	usd
CY2020	us-gaap	Selling Expense SellingExpense	1555546	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2602624	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3296844	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1703424	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7644375	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5465662	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	583125	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	29330134	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	11736037	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	3842095	usd
CY2022	upc	Income From Operation IncomeFromOperation	7438798	usd
CY2021	upc	Income From Operation IncomeFromOperation	-13590140	usd
CY2020	upc	Income From Operation IncomeFromOperation	-10251725	usd
CY2022	us-gaap	Interest Expense InterestExpense	162400	usd
CY2021	us-gaap	Interest Expense InterestExpense	101604	usd
CY2020	us-gaap	Interest Expense InterestExpense	123760	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	48940	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-80434	usd
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-49352	usd
CY2022	upc	Shortterm Investment Income ShorttermInvestmentIncome	470477	usd
CY2021	upc	Shortterm Investment Income ShorttermInvestmentIncome	-239549	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	38588	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	30827	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	21820	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-545349	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	88338	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-151292	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7984147	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13678478	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10100433	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	752419	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2358526	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2542211	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8736566	usd
CY2021	us-gaap	Profit Loss ProfitLoss	11319952	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	3755464	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1193369	usd
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-860623	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	12513321	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	8418845	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.4
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.6
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21750000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18980822	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16000000	shares
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	12384059	usd
CY2020	us-gaap	Profit Loss ProfitLoss	7558222	usd
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	860623	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	20802904	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28750000	usd
CY2021	upc	Stock Issued During Period Value Capitalized Initial Public Offering Costs StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts	-3131872	usd
CY2021	us-gaap	Profit Loss ProfitLoss	11319952	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1193369	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	58934353	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8736566	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3755464	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46442323	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8736566	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	11319952	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7558222	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	533949	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	446878	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	410079	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	983	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1559	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	419353	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-230175	usd
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	98102	usd
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	15774	usd
CY2020	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-75391	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-605278	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-668341	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9886	usd
CY2022	upc	Shortterm Investments Income ShorttermInvestmentsIncome	470477	usd
CY2021	upc	Shortterm Investments Income ShorttermInvestmentsIncome	-239549	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1549312	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3867457	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4107520	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-16586	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	451634	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-888607	usd
CY2022	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	-2681214	usd
CY2021	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	2717085	usd
CY2022	us-gaap	Increase Decrease In Prepaid Advertising IncreaseDecreaseInPrepaidAdvertising	-7385695	usd
CY2021	us-gaap	Increase Decrease In Prepaid Advertising IncreaseDecreaseInPrepaidAdvertising	7434240	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-236982	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	237720	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1699929	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	168188	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12407	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1896621	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2457337	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	639427	usd
CY2022	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	-904127	usd
CY2021	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	-298620	usd
CY2020	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	731518	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2318474	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	31436	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-30408	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1312346	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2055847	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6115157	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	93703	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	444505	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51798	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	523	usd
CY2021	upc	Prepayments Made To A Related Party For Purchase Of Property PrepaymentsMadeToARelatedPartyForPurchaseOfProperty	2457600	usd
CY2021	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction	10629120	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	3814925	usd
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	15330660	usd
CY2021	upc	Redemption Of Shortterm Investments RedemptionOfShorttermInvestments	1801927	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3908105	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27059958	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51798	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	4272716	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	4300800	usd
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1427000	usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	4272716	usd
CY2021	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	2764800	usd
CY2020	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	1427000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	28750000	usd
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2792543	usd
CY2020	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	441064	usd
CY2022	upc	Proceeds Fromprepayments For Related Parties Borrowings ProceedsFromprepaymentsForRelatedPartiesBorrowings	-3317943	usd
CY2021	upc	Proceeds Fromprepayments For Related Parties Borrowings ProceedsFromprepaymentsForRelatedPartiesBorrowings	911648	usd
CY2020	upc	Proceeds Fromprepayments For Related Parties Borrowings ProceedsFromprepaymentsForRelatedPartiesBorrowings	-911200	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3317943	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26581809	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	470136	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-463942	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	553702	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	347386	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2366450	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1980294	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6880881	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8077908	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10058202	usd
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3177321	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5711458	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8077908	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10058202	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	199852	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	149303	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	157528	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	2748629	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	3271219	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	2167963	usd
CY2021Q1	upc	Shares Issued01 SharesIssued01	5000000	shares
CY2021Q1	us-gaap	Share Price SharePrice	0.003125
CY2021Q1	upc	Public Offering Price PublicOfferingPrice	5
CY2021Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	28750000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Uses of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operation of the Company is located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s operations may be further affected by the ongoing COVID-19 pandemic. Due to the resurgence of COVID-19 pandemic in China in 2022, there had been delays in purchase of raw material supplies and deliver products to the customers of the PRC operating entities on a timely basis as a consequence of the travel restrictions. The prices of the raw materials also increased by about 5% from January 2022 to May 2022 as compared to the same period last year. In addition, the Company has granted some of its customers extended payment terms of 30 days to 120 days since January 2022, as a result of the COVID-19 pandemic. However, based on the present relationship with these customers and the evaluation of their financial health, the Company does not anticipate any material collectability problems. Even though the Company does not expect that the COVID-19 pandemic will have a negative impact on the business operations of the PRC operating entities and the financial results, due to the high uncertainty of the evolving situation, the Company has limited visibility on how the COVID-19 pandemic affects the execution of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with COVID-19 may cause the revenue and cash flows to underperform in the next 12 months from the date the consolidated financial statements are released. The extent of the future impact of the COVID-19 pandemic on the business and results of operations is still uncertain. Any resurgence of the COVID-19 pandemic could negatively affect the execution of customer contracts, the collection of customer payments, or disrupt the Company’s supply chain, and the continued uncertainties associated with COVID-19 may negatively impact the Company’s revenue and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	upc	Material Price Percentage MaterialPricePercentage	0.05	pure
CY2022	upc	Allowance For Uncollectable Balances Amount AllowanceForUncollectableBalancesAmount	791827	usd
CY2021	upc	Allowance For Uncollectable Balances Amount AllowanceForUncollectableBalancesAmount	446527	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	120286	usd
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	116453	usd
CY2022	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	702890	usd
CY2022	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	5000000	cny
CY2021	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	744924	usd
CY2021	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	5000000	cny
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	38588	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	30827	usd
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	21820	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1316654	usd
CY2020	us-gaap	Advertising Expense AdvertisingExpense	343962	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7644375	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5465662	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	583125	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	17527318	usd
CY2022	upc	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2022	upc	Percentage Of Vat Rate PercentageOfVatRate	0.17	pure
CY2022	upc	Description Of Year End Spot Rate DescriptionOfYearEndSpotRate	US$1=RMB7.1135
CY2021	upc	Description Of Year End Spot Rate DescriptionOfYearEndSpotRate	US$1=RMB6.4580
CY2022	upc	Accounts Receivable Description AccountsReceivableDescription	The Company’s accounts receivable primarily includes the balance due from customers when the Company’s pharmaceutical products are sold and delivered to customers. All of the Company’s accounts receivable balance at September 30, 2021 has been collected in the fiscal year 2022. As of date of this report, approximately 71.9%, or $10.9 million, of the Company’s net account receivable balance at September 30, 2022 has been subsequently collected and the remaining balance is expected to be substantially collected before March 31, 2023.
CY2020	upc	Description Of Year End Spot Rate DescriptionOfYearEndSpotRate	US$1=RMB6.8033
CY2022	upc	Description Of Average Rate DescriptionOfAverageRate	US$1=RMB6.5532
CY2021	upc	Description Of Average Rate DescriptionOfAverageRate	US$1=RMB6.5095
CY2020	upc	Description Of Average Rate DescriptionOfAverageRate	US$1=RMB7.0077
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	465689	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	617145	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	347312	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	15975717	usd
CY2021Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	16020269	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	791827	usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	446527	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15183890	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15573742	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	15975717	usd
CY2022Q3	upc	Sunsequent Collections Total Gross Accounts Receivable SunsequentCollectionsTotalGrossAccountsReceivable	10918976	usd
CY2022	upc	Total Gross Accounts Receivable Percentage TotalGrossAccountsReceivablePercentage	0.683	pure
CY2022Q3	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	791827	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	15183890	usd
CY2022Q3	upc	Sunsequent Collection Accounts Receivable Net SunsequentCollectionAccountsReceivableNet	10918976	usd
CY2022	upc	Accounts Receivable Net Percentage AccountsReceivableNetPercentage	0.719	pure
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	446527	usd
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	639991	usd
CY2022	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	419353	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	225660	usd
CY2022	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-74053	usd
CY2021	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	32196	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	791827	usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	446527	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	989043	usd
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	607661	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1337731	usd
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1971334	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	120286	usd
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	116453	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	2206488	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	2462542	usd
CY2022	upc	Schedule Of Advances To Suppliers Net ScheduleOfAdvancesToSuppliersNet	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Advances to suppliers for inventory raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,738,313</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Advances to suppliers, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,701</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,738,313</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p>
CY2022Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	16701	usd
CY2021Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2738313	usd
CY2022	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	16701	usd
CY2021	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	2738313	usd
CY2021Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	55000000	cny
CY2021Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	8500000	usd
CY2021Q3	upc	Percentage Of Advance Payment PercentageOfAdvancePayment	0.30	pure
CY2021Q3	upc	Additional Contract Price Percentage AdditionalContractPricePercentage	0.58	pure
CY2021Q3	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	48400000	cny
CY2021Q3	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	7500000	usd
CY2022	upc	Contract Price Percentage ContractPricePercentage	0.12	pure
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	6600000	cny
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	900000	usd
CY2022Q3	upc	Asset Acquisition Price Of Acquisitions Expected AssetAcquisitionPriceOfAcquisitionsExpected	10100000	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	25000000	cny
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	3500000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4250638	usd
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	13725204	usd
CY2021	upc	Add Purchase Wealth Management Financial Products AddPurchaseWealthManagementFinancialProducts	15330660	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1801927	usd
CY2022	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-470477	usd
CY2021	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	239549	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-106133	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-43078	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	13148594	usd
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	13725204	usd
CY2022Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	470477	usd
CY2021Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	239549	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9960736	usd
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10461600	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5710098	usd
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5780247	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4681353	usd
CY2022	us-gaap	Depreciation Depreciation	528919	usd
CY2021	us-gaap	Depreciation Depreciation	441355	usd
CY2020	us-gaap	Depreciation Depreciation	404948	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	983	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1559	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	273974	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	301691	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-116523	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-123208	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	157451	usd
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	178483	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5030	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5523	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5131	usd
CY2022Q3	us-gaap	Construction Contract Cost Progress Payment Offset ConstructionContractCostProgressPaymentOffset	2900000	cny
CY2022	upc	Capital Expenditure CapitalExpenditure	3500000	usd
CY2020	us-gaap	Interest And Debt Expense InterestAndDebtExpense	157528	usd
CY2021Q2	upc	Equity Interest EquityInterest	0.05	pure
CY2021Q2	upc	Office Space Square Meters OfficeSpaceSquareMeters	2749	pure
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	32000000	cny
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	4500000	usd
CY2021Q2	upc	Percentage Of Prepayment PercentageOfPrepayment	0.50	pure
CY2021Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.20	pure
CY2021Q2	upc	Payable Delivery Property Percentage PayableDeliveryPropertyPercentage	0.30	pure
CY2022	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	16000000	cny
CY2022	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	2250000	usd
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	3936184	usd
CY2021Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	4334400	usd
CY2021Q2	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	10000000	cny
CY2021Q2	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	1548000	usd
CY2021Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2021Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-06-30
CY2021Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.045	pure
CY2022Q2	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	10000000	cny
CY2022Q2	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	1405780	usd
CY2022Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-06-24
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.042	pure
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	199852	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	149303	usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	236982	usd
CY2022Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	3379263	usd
CY2021Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	19723	usd
CY2021Q2	us-gaap	Deconsolidation Related Party Description DeconsolidationRelatedPartyDescription	As disclosed in Note 12, on May 6, 2021, the Company entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, to purchase certain residential apartment and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.5 million).
CY2022	upc	Prepayment Amount PrepaymentAmount	16000000	cny
CY2022	upc	Prepayment Amount PrepaymentAmount	-2249248	usd
CY2022Q1	upc	Equity Interest Ownership Percentage EquityInterestOwnershipPercentage	0.05	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.25	pure
CY2022	upc	Preferential Tax Treatment Description PreferentialTaxTreatmentDescription	Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one of the Company’s main operating subsidiaries in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning November 2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. In November 2022, Jiangxi Universe successfully further renewed its HNTE certification with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through November 2025. Universe Trade, another operating subsidiary of the Company in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three years through December 2023. EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years ended September 30, 2022, 2021 and 2020 were reported at a blended reduced rate as a result of certain of the PRC subsidiaries of the Company’s being approved as a HNTE and enjoying a 15% reduced income tax rate.
CY2022Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	694955	usd
CY2021Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	1518979	usd
CY2020Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	118986	usd
CY2022	us-gaap	Income Tax Holiday Income Tax Benefits Per Share IncomeTaxHolidayIncomeTaxBenefitsPerShare	0.03
CY2021	us-gaap	Income Tax Holiday Income Tax Benefits Per Share IncomeTaxHolidayIncomeTaxBenefitsPerShare	0.09
CY2020	us-gaap	Income Tax Holiday Income Tax Benefits Per Share IncomeTaxHolidayIncomeTaxBenefitsPerShare	0.01
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	869997	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1347672	usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	869997	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1357697	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3026867	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2552097	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	752419	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2358526	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2542211	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.087	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.11	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.011	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	-0.223	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.034	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.02	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.013	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.006	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.005	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.094	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.171	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.252	pure
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1210855	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	785550	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	136817	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	84447	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1347672	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001809616
CY2021Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	669780	usd
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	115087	usd
CY2021Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	326468	usd
CY2022Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	52263	usd
CY2021Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	105212	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	167350	usd
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	1101460	usd
CY2022Q3	us-gaap	Foreign Financial Institutions Mandated Deposits ForeignFinancialInstitutionsMandatedDeposits	5711423	usd
CY2021Q3	us-gaap	Foreign Financial Institutions Mandated Deposits ForeignFinancialInstitutionsMandatedDeposits	5892655	usd
CY2021Q3	us-gaap	Shares Outstanding SharesOutstanding	21750000	shares
CY2022Q3	us-gaap	Shares Issued SharesIssued	21750000	shares
CY2022	upc	Reserve Is Equal Percentage ReserveIsEqualPercentage	0.50	pure
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5211231	usd
CY2022	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	13500000	usd
CY2022	us-gaap	Interest Expense Capital Securities InterestExpenseCapitalSecurities	3500000	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2022	us-gaap	Cost Of Other Property Operating Expense CostOfOtherPropertyOperatingExpense	23988177	usd
CY2021	us-gaap	Cost Of Other Property Operating Expense CostOfOtherPropertyOperatingExpense	29559286	usd
CY2020	us-gaap	Cost Of Other Property Operating Expense CostOfOtherPropertyOperatingExpense	18374751	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16154974	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18422745	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12329209	usd
CY2022	us-gaap	Revenues Revenues	40143151	usd
CY2021	us-gaap	Revenues Revenues	47982031	usd
CY2020	us-gaap	Revenues Revenues	30703960	usd
CY2022	upc	Subtotal Of Tcmd Products Sales SubtotalOfTCMDProductsSales	23988177	usd
CY2021	upc	Subtotal Of Tcmd Products Sales SubtotalOfTCMDProductsSales	29559286	usd
CY2020	upc	Subtotal Of Tcmd Products Sales SubtotalOfTCMDProductsSales	18374751	usd
CY2022	upc	Subtotal Of Thirdparty Products Sales SubtotalOfThirdpartyProductsSales	16154974	usd
CY2021	upc	Subtotal Of Thirdparty Products Sales SubtotalOfThirdpartyProductsSales	18422745	usd
CY2020	upc	Subtotal Of Thirdparty Products Sales SubtotalOfThirdpartyProductsSales	12329209	usd
CY2022	us-gaap	Revenues Revenues	40143151	usd
CY2021	us-gaap	Revenues Revenues	47982031	usd
CY2020	us-gaap	Revenues Revenues	30703960	usd
CY2022	us-gaap	Subsequent Event Description SubsequentEventDescription	The Company evaluated the subsequent event through the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed.
CY2022Q3	upc	Minority Interests Ownership Percentage By Parent MinorityInterestsOwnershipPercentageByParent	0.25	pure
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2020	upc	Shortterm Investment Income ShorttermInvestmentIncome		usd
CY2020	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
CY2021	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge		usd
CY2020	upc	Shortterm Investments Income ShorttermInvestmentsIncome		usd
CY2020	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies		usd
CY2020	us-gaap	Increase Decrease In Prepaid Advertising IncreaseDecreaseInPrepaidAdvertising		usd
CY2020	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2022	upc	Prepayments Made To A Related Party For Purchase Of Property PrepaymentsMadeToARelatedPartyForPurchaseOfProperty		usd
CY2020	upc	Prepayments Made To A Related Party For Purchase Of Property PrepaymentsMadeToARelatedPartyForPurchaseOfProperty		usd
CY2022	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction		usd
CY2020	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction		usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments		usd
CY2020	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments		usd
CY2022	upc	Redemption Of Shortterm Investments RedemptionOfShorttermInvestments		usd
CY2020	upc	Redemption Of Shortterm Investments RedemptionOfShorttermInvestments		usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends		usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends		usd
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-010349-index-headers.html	Edgar Link	pending
0001213900-23-010349-index.html	Edgar Link	pending
0001213900-23-010349.txt	Edgar Link	pending
0001213900-23-010349-xbrl.zip	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
ex15-1_002.jpg	Edgar Link	pending
ex15-2_001.jpg	Edgar Link	pending
ex15-3_001.jpg	Edgar Link	pending
ex4-11_001.jpg	Edgar Link	pending
ex4-11_002.jpg	Edgar Link	pending
ex4-11_003.jpg	Edgar Link	pending
ex4-11_004.jpg	Edgar Link	pending
ex4-11_005.jpg	Edgar Link	pending
ex4-11_006.jpg	Edgar Link	pending
ex4-11_007.jpg	Edgar Link	pending
ex4-12_001.jpg	Edgar Link	pending
ex4-12_002.jpg	Edgar Link	pending
ex4-12_003.jpg	Edgar Link	pending
ex4-12_004.jpg	Edgar Link	pending
ex4-12_005.jpg	Edgar Link	pending
ex4-12_006.jpg	Edgar Link	pending
ex4-12_007.jpg	Edgar Link	pending
ex4-12_008.jpg	Edgar Link	pending
ex4-12_009.jpg	Edgar Link	pending
ex4-12_010.jpg	Edgar Link	pending
ex4-12_011.jpg	Edgar Link	pending
ex4-12_012.jpg	Edgar Link	pending
ex4-12_013.jpg	Edgar Link	pending
ex4-12_014.jpg	Edgar Link	pending
ex4-12_015.jpg	Edgar Link	pending
ex4-12_016.jpg	Edgar Link	pending
ex4-13_001.jpg	Edgar Link	pending
ex4-13_002.jpg	Edgar Link	pending
ex4-13_003.jpg	Edgar Link	pending
ex4-14_001.jpg	Edgar Link	pending
ex4-14_002.jpg	Edgar Link	pending
ex4-14_003.jpg	Edgar Link	pending
ex4-14_004.jpg	Edgar Link	pending
ex4-14_005.jpg	Edgar Link	pending
f20f2022ex12-1_universe.htm	Edgar Link	pending
f20f2022ex12-2_universe.htm	Edgar Link	pending
f20f2022ex13-1_universe.htm	Edgar Link	pending
f20f2022ex13-2_universe.htm	Edgar Link	pending
f20f2022ex15-1_universe.htm	Edgar Link	pending
f20f2022ex15-2_universe.htm	Edgar Link	pending
f20f2022ex15-3_universe.htm	Edgar Link	pending
f20f2022ex2-3_universe.htm	Edgar Link	pending
f20f2022ex4-11_universe.htm	Edgar Link	pending
f20f2022ex4-12_universe.htm	Edgar Link	pending
f20f2022ex4-13_universe.htm	Edgar Link	pending
f20f2022ex4-14_universe.htm	Edgar Link	pending
f20f2022_universe.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
f20f2022_universe_htm.xml	Edgar Link	completed
img_002.jpg	Edgar Link	pending
img_003.jpg	Edgar Link	pending
img_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
upc-20220930.xsd	Edgar Link	pending
upc-20220930_cal.xml	Edgar Link	unprocessable
upc-20220930_def.xml	Edgar Link	unprocessable
upc-20220930_lab.xml	Edgar Link	unprocessable
upc-20220930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UPC
Universe Pharmaceuticals Inc Stock $upc

2022 Q3 Form 20-F Financial Statement

#000121390023010349 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UPC Universe Pharmaceuticals Inc Stock $upc

2022 Q3 Form 20-F Financial Statement

#000121390023010349 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UPC
Universe Pharmaceuticals Inc Stock $upc